§ 35-48-2-12 — Schedule V

Indiana § 35-48-2-12

• Jurisdiction: Indiana
• Art. 48: CONTROLLED SUBSTANCES
• Ch. 2: Classification of Drugs

Text

(a) The controlled substances listed in this
section are included in schedule V.
(b) Narcotic drugs containing nonnarcotic active medicinal
ingredients. Any compound, mixture, or preparation containing any of
the following narcotic drugs, or their salts calculated as the free
anhydrous base or alkaloid, in the following quantities, which shall
include one (1) or more nonnarcotic active medicinal ingredients in
sufficient proportion to confer upon the compound, mixture, or
preparation, valuable medicinal qualities other than those possessed by
the narcotic drug alone:
(1) Not more than 200 milligrams of codeine per 100 milliliters
or per 100 grams.
(2) Not more than 100 milligrams of dihydrocodeine per 100
milliliters or per 100 grams.
(3) Not more than 100 milligrams of ethylmorphine per 100
milliliters or per 100 grams.
(4) Not more than 2.5 milligrams of diphenoxylate and not less
than 25 micrograms of atropine sulfate per dosage unit.
(5) Not more than 100 milligrams of opium per 100 milliliters or
per 100 grams.
(6) Not more than 0.5 milligrams of difenoxin (9168), and not less
than 25 micrograms of atropine sulfate per dosage unit.
(c) Stimulants. Unless specifically exempted or excluded or unless
listed in another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following substance
having a stimulant effect on the central nervous system, including its
salts, isomers, and salts of isomers: Pyrovalerone (1485).
(d) Depressants. Unless specifically exempted or excluded or unless
listed in another schedule, any material, compound, mixture, or
preparation which contains any quantity of the following substances
having a depressant effect on the central nervous system, including its
salts:
(1) Brivaracetam ((2S)-2-[(4R)-2-oxo- 4-propylpyrrolidin-1-yl]
butanamide) (also referred to as BRV; UCB-34714; Briviact)
(including its salts) (2710).
(2) Cenobamate ([(1R)-1- (2-chlorophenyl)-2-
(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol,
alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic
acid (R)-(+)-1-(2-chlorophenyl)-2- (2H-tetrazol-2-yl)ethyl ester)
(2720).
(3) Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-
carbamic acid ethyl ester] (2779).
(4) Ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one)
(2401).
(5) Lacosamide [(R)-2-acetoamido-N-benzyl-3-
methoxy-propionamide] (2746).
(6) Lasmiditan [2,4,6-trifluoro-N-
(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide]
(2790).
(7) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid]
(2782).
As added by Acts 1976, P.L.148, SEC.7. Amended by Acts
1979, P.L.303, SEC.7; Acts 1981, P.L.170, SEC.6; P.L.327-1985,
SEC.3; P.L.22-2008, SEC.5; P.L.283-2013, SEC.4; P.L.119-2019,
SEC.6; P.L.61-2020, SEC.8; P.L.10-2021, SEC.2; P.L.48-2023,
SEC.7.